Healthcare Services

A Significant Growth Driver for the Next Generation Cancer Diagnostics Market Is the The Rise In Demand For Personalized Medicines Driving The Growth Of The Market Due To Increasing Prevalence Of Chronic And Rare Diseases

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Next Generation Cancer Diagnostics Market Across 2026–2030?

The next generation cancer diagnostics market has experienced significant expansion in recent years. This market is projected to expand from $14.4 billion in 2025 to $16.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. Historically, this growth has been driven by factors such as the rising incidence of cancer, breakthroughs in genomic sequencing technologies, wider clinical acceptance of diagnostics based on biomarkers, increased funding for oncology research, and a growing need for precise diagnostic methods.

The market for next generation cancer diagnostics is projected to experience substantial expansion in the coming years. It is anticipated to reach $26.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. This expansion over the forecast period stems from factors such as the greater acceptance of personalized medicine approaches, increased funding for sophisticated cancer screening initiatives, the wider application of minimally invasive diagnostic techniques, the growth in companion diagnostics development, and the deeper incorporation of AI-powered clinical decision support. Key developments foreseen during this period encompass the accelerated embrace of liquid biopsy technologies, the expanding utilization of multi-omics diagnostic platforms, the deepening integration of AI-based cancer analytics, the widening scope of personalized oncology diagnostics, and a heightened emphasis on identifying cancer at its initial stages.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Next Generation Cancer Diagnostics Market?

A rising demand for personalized medicines is anticipated to boost the expansion of the next generation cancer diagnostics market in the future. These medicines represent medical interventions customized to a person’s genetic composition, way of life, and surroundings, aiming to deliver the most effective treatment for their particular case. This growing need for personalized medicines stems from the increasing occurrence of chronic and rare diseases, which require precise, patient-focused therapies to achieve better treatment results. Next generation cancer diagnostics facilitate personalized medicine by offering accurate molecular data that informs customized treatment approaches, considering an individual patient’s distinct genetic and tumor characteristics. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA sanctioned 16 novel personalized therapies for individuals suffering from rare diseases, indicating a significant increase from the six approvals noted in 2022. Consequently, the expanding requirement for personalized medicines is fueling the development of the next generation cancer diagnostics market.

What Segmentation Levels Are Considered In The Next Generation Cancer Diagnostics Market?

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

What Industry Trends Are Redefining The Next Generation Cancer Diagnostics Market?

Leading companies in the next generation cancer diagnostics market are concentrating on developing innovative solutions, including artificial intelligence-driven multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These AI-driven multi-modal diagnostic platforms are advanced systems that utilize artificial intelligence to integrate and analyze various types of biological data, such as genomic, proteomic, imaging, and clinical information, for more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform specifically designed for precision oncology. The platform combines diverse data types, including circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. By employing a 1080-gene panel powered by AI and machine learning, OncoIncytes delivers highly sensitive and specific insights to enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform facilitates personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.

Which Leading Firms Are Contributing To The Growth Of The Next Generation Cancer Diagnostics Market?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Read the full next generation cancer diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Which Regions Are Projected To Dominate The Next Generation Cancer Diagnostics Market In The Coming Years?

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Cancer Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30336&type=smp

Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company

Peripheral Neuropathy Global Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Chronic Pain Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuralgia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795